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A B S T R A C T
Background
Heparin as an adjunct in assisted reproduction (peri-implantation heparin) is given at or after egg collection or at embryo transfer.
Heparin has been advocated to improve embryo implantation and clinical outcomes. It is proposed that heparin may enhance the intra-
uterine environment by improving decidualisation with an associated activation of growth factors and a cytokine expression profile in
the endometrium that is favourable to pregnancy.
Objectives
To investigate whether the administration of heparin around the time of implantation (peri-implantation heparin) improves clinical
outcomes in subfertile women undergoing assisted reproduction.
Search methods
A comprehensive and exhaustive search strategy was developed in consultation with the Trials Search Co-ordinator of the Cochrane
Menstrual Disorders and Subfertility Group (MDSG). The strategy was used in an attempt to identify all relevant studies regardless of
language or publication status (published, unpublished, in press, and in progress). Relevant trials were identified from both electronic
databases and other resources (last search 6 May 2013).
Selection criteria
All randomised controlled trials (RCTs) were included where peri-implantation heparin was given during assisted reproduction. Live
birth rate was the primary outcome.
Data collection and analysis
Two review authors independently assessed the eligibility and quality of trials and extracted relevant data. The quality of the evidence
was evaluated using GRADE methods.
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Main results
Three RCTs (involving 386 women) were included in the review. Peri-implantation low molecular weight heparin (LMWH) during
IVF/ICSI was given at or after egg collection or at embryo transfer in these studies. The characteristics of the participants differed across
studies. One included women having their first IVF cycle, with no blood clotting disorder; another included women with at least one
blood clotting disorder and the third included women who had undergone at least two previous unsuccessful ART cycles.
Our findings differed according to choice of statistical model. When we used a fixed effect analysis, the evidence suggested that peri-
implantation heparin was associated with an improvement in live birth rate compared with placebo or no heparin (odds ratio (OR) 1.77,
95% confidence interval (CI) 1.07 to 2.90, three studies, 386 women, I2 = 51%, very low quality evidence) and also an improvement
in the clinical pregnancy rate (OR 1.61, 95% CI 1.03 to 2.53, three studies, 386 women, I2 = 29%, low quality evidence). However
when a random effects model was used there was no longer a difference between the groups for either live birth (OR 1.85, 95% CI 0.80
to 4.24) or clinical pregnancy (OR 1.66, 95% CI 0.94 to 2.90). Moreover there was high heterogeneity (I2 = 51%) for the analysis of
live birth.
Adverse events were poorly reported in all the included studies. Events such as bleeding, and thrombocytopenia were reported in women
receiving heparin and affected 5-7% of women in the heparin group in one study. However no studies reported data suitable for analysis
and so no firm conclusions could be drawn regarding adverse effects.
The main limitations in the evidence were inconsistency, imprecision and inadequate reporting of adverse events.
Authors’ conclusions
It is unclear whether peri-implantation heparin in assisted reproduction treatment (ART) cycles improves live birth and clinical
pregnancy rates in subfertile women, as the evidence was sensitive to choice of statistical model and no benefit was apparent when a
random effects model was used. Side effects have been reported with use of heparin and no firm conclusions can be drawn regarding
its safety. Our results do not justify the use of heparin in this context, except in well-conducted research trials.
These findings need to be further investigated with well-designed, adequately powered, double-blind, randomised, placebo-controlled,
multicentre trials. Further investigations could also focus on the effects of the local (uterine) and non-systemic application of heparin
during ART.
P L A I N L A N G U A G E S U M M A R Y
Heparin for assisted reproduction
Review Question
Researchers in the Cochrane Collaboration reviewed the evidence about the effect of heparin administered around the time of implan-
tation on clinical outcomes in subfertile women undergoing assisted reproduction.
Background
Heparin is a class of blood thinning drug that is used in the prevention and treatment of blood clots. It has been suggested that heparin
may improve the intrauterine environment in subfertile women, by increasing growth factors to improve attachment of the embryo to
the lining of the womb. The result could be an improvement in live birth rates during assisted reproduction.
Study Characteristics
Three studieswith 386participantswere included in the review.All participantswere subfertile womenundergoing assisted reproduction.
Their characteristics differed across studies. One study included women having their first IVF cycle, with no blood clotting disorder.
Another study included women with at least one blood clotting disorder. The third study included women with at least two previous
unsuccessful assisted reproduction treatment cycles. In all cases a daily injection of low molecular weight heparin was given to women
from the time of egg collection or embryo transfer during assisted reproduction. Control groups received placebo or no treatment.
There were no issues with source of funding in any of the studies. The evidence is current to May 2013.
Key Results
It is unclear whether peri-implantation heparin in assisted reproduction treatment (ART) cycles improves live birth and clinical
pregnancy rates in subfertile women. Although there was some suggestion of benefit, this disappeared when an alternative method
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of analysis was used. Heparin had side effects such as bruising and bleeding, but no conclusions could be drawn regarding its safety
because none of the studies reported comparative data on adverse effects. The evidence does not justify the use of heparin except in
well-designed clinical research trials. Such trials are a priority.
Quality of Evidence
The evidence was of low or very low quality, mainly due to imprecision, inconsistency and inadequate reporting of advere events.
Further well-designed randomised controlled trials with larger sample sizes are needed to clarify the possible role of heparin in assisted
reproduction.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Heparin for assisted reproduction
Population: Subfertile women
Settings: Assisted reproduction treatment (ART)
Intervention: Heparin versus placebo or no heparin
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI) using fixed ef-
fect model
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Heparin
Live birth rate per
woman
173 per 1000 271 per 1000
(183 to 378)
OR 1.77
(1.07 to 2.9)
386
(3 studies)
⊕©©©
very low1,2
Estimate using random
effects model: OR 1.85,
95% CI 0.80 to 4.24
Clinical pregnancy rate
per woman
250 per 1000 349 per 1000
(256 to 458)
OR 1.61
(1.03 to 2.53)
386
(3 studies)
⊕©©©
low2
Estimate using random
effects model: OR 1.66,
95% CI 0.94 to 2.90
Adverse effects No comparative data available so no conclusions could be drawn. Adverse effects such as bleeding, and thrombocytopenia were reported in the heparin groups
and affected 5-7% of women in one study
*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Inconsistency (high heterogeneity: I2=51%)
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2 Imprecision: low overall event rate, confidence intervals compatible with substantial benefit or no appreciable benefit, findings sensitive
to choice of statistical model. Random effects model gives non-significant findings
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B A C K G R O U N D
Description of the condition
Infertility is the failure of a couple of reproductive age to conceive
after having regular unprotected sexual intercourse for a period of
12 months or more. Primary infertility refers to couples who have
never conceived, and secondary infertility refers to couples who
have previously conceived but are unable to do so again after a
year of trying.
Infertility affects 15% of couples and is becoming increasingly
common. Of these couples, 70% will have primary and 30% sec-
ondary infertility. Assisted reproduction techniques (ART) have
been employed to help some of these couples achieve a pregnancy.
Assisted reproduction has significant physical, social, psychologi-
cal and financial implications. The success of ART can be defined
as the live birth of a child. Live birth rates with ART vary from
30% to 50%; hence various adjuncts have been employed during
assisted reproduction to increase the likelihood of pregnancy and
live birth. The effectiveness of these adjuncts remains to be de-
termined in many cases. Heparin, given as an adjunct to women
with or without a known thrombophilia, is one such therapy and
has been suggested as being efficacious in improving implantation
(attachment of the fertilised egg to the wall of the uterus) and
achieving pregnancy.
Description of the intervention
Heparan sulphates have an important role in conception and early
pregnancy events. However the role of heparin (a structural ana-
logue of heparan) in assisted conception is not clear. Heparin is a
linear polydisperse polysaccharide consisting of 1-4 linked pyra-
nosyluronic acid and 2-amino-deoxyglucopyranose (glucosamine)
residues (Comper 1981). Owing to their highly anionic nature,
heparin and heparan sulphate have high binding affinity to an-
tithrombin, growth factors, growth factor receptors, viral envelope
proteins and extracellular matrix molecules.
Heparan sulphate proteoglycans (HSPGs) are expressed through-
out the reproductive tract and are involved in the regulation of
endometrial cycling (Potter 1992; Kelly 1995, San Martin 2004;
Germeyer 2007; Lai 2007; Xu 2007).
Low molecular weight heparins (LMWH) are derived from hep-
arin by enzymatic (for example tinzaparin) or chemical (for exam-
ple dalteparin, nadroparin and enoxaparin) depolymerisation of
unfractionated heparin (UFH), which in itself cannot be synthe-
sised in vitro.
Unfractionated heparin and LMWH facilitate the anticoagulant
effect of antithrombin (Bick 2005) but, compared with unfrac-
tionated heparin, LMWH has reduced antifactor IIa activity lead-
ing to inefficient inhibition of thrombin by antithrombin. How-
ever, the smallerweight LMWHinactivates factorXawith equal ef-
ficacy. Low molecular weight heparin has a longer half-life, a more
predictable antithrombotic response, and a substantially lower risk
of heparin-induced thrombocytopenia (HIT) (Warkentin 1995;
Warkentin 2004) and osteoporosis (Murray 1995), thus having
obvious clinical benefits. So in practice, LMWH is used routinely
with daily self-administered subcutaneous injections, not requir-
ing close monitoring and with lower risk of side effects.
Low molecular weight heparins have a mean molecular weight of
4300 to 5000 kDa (range 1000 to 10,000 kDa), compared to
15,000 kDa for unfractionated heparin (Nelson 2008).
How the intervention might work
Implantation is a complex, dynamic process which involves co-
ordination of various interactions at an intra- and intercellular
level. The interaction between the developing embryo and the en-
dometrium is still not fully understood; however heparin can po-
tentially modulate many of the known mechanisms that underlie
the successful implantation of the developing embryo.
Traditionally the role of heparin in early pregnancy was believed to
be in the preventionof blood clotting during implantation andpla-
centation in women with inherited and acquired thrombophilia.
However, more recent work suggests a possible therapeutic role
for heparin in other mechanisms fundamental to implantation.
Unfractionated heparin as well as LMWH are able to modulate
the process of decidualisation, whereby the cells in the lining of
the womb prepare for pregnancy. This positive effect on decid-
ualisation is a potential mechanism by which heparin improves
implantation in ART (Corvinus 2003, Poehlmann 2005, Fluhr H
2010).
Heparin also has the ability to bind with and modulate a wide
variety of proteins, which can influence a number of physiologi-
cal processes involved in implantation and trophoblastic develop-
ment. These processes include adhesion of the blastocyst to the
endometrial surface (Wang 2002) and trophoblastic differentia-
tion and invasion (Arai 1994;Weigert 2001; Leach 2004; Quenby
2004; Erden 2006; Moller 2006; Di Simone 2007; d’Souza 2007;
Nelson 2008).
Why it is important to do this review
Heparin is often offered to couples as an adjunct in an attempt
to improve live birth rates, its presumed effect being to improve
implantation. Clinicians may be using heparin as an adjunct based
on biological plausibility rather than evidence of efficacy. A sys-
tematic review is required to determine the efficacy of heparin to
increase pregnancy and live birth rates and reduce adverse perina-
tal outcomes for all women undergoing assisted reproduction.
When heparin is used as an adjunct treatment during assisted
reproduction, there has been no consensus regarding the optimum
type of heparin (unfractionated heparin or LMWH) timing or the
dose. This is an area which we considered in the review.
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This Cochrane review aims to provide evidence about the efficacy
of heparin given in the peri-implantation period (around the time
of conception) to reduce implantation failure in women who have
a history of infertility and are undergoing assisted reproduction
treatments. In this review we do not assess the efficacy of heparin
as an anti-thrombophilic agent (preventing blood clots) later in
pregnancy or in women with a history of recurrent miscarriage.
O B J E C T I V E S
To investigate whether the administration of heparin around the
time of implantation improves clinical outcomes in subfertile
women undergoing assisted reproduction.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
We included trials of women undergoing assisted reproduction
treatment (ART) with a history of infertility. Trials of women with
a previously known thrombophilia were included.
Trials involving women undergoing stimulated or unstimulated
intrauterine insemination (IUI) were not included.
Types of interventions
1. Heparin versus no treatment.
2. Heparin versus placebo.
3. Heparin versus aspirin.
4. Heparin versus heparin and aspirin.
5. Unfractionated heparin (UFH) versus low molecular weight
heparin (LMWH).
Studies were included if heparin was administered in the peri-
implantation period (from the day of egg collection or embryo
transfer (ET) to 14 days later).
Types of outcome measures
Primary outcomes
1. Live birth rate per woman. Number of live births divided
by the number of randomised women (live birth is defined as
delivery of one or more live infants).
2. Adverse effects of heparin e.g. any bleeding, bruising,
heparin-induced thrombocytopenia (HIT), anaphylaxis and any
other unexpected side effects.
Secondary outcomes
1. Clinical pregnancy rate per randomised woman. The
presence of at least one gestational sac with fetal heart beat on
ultrasound scan defines a clinical pregnancy.
2. Multiple pregnancy rate per randomised woman. The
demonstration of more than one sac with a fetal pole on
ultrasound scan defines multiple pregnancies.
3. Maternal pregnancy complications including first trimester
miscarriage, second trimester miscarriage, preterm delivery, pre-
eclampsia, pregnancy-induced hypertension, any maternal
bleeding.
4. Fetal complications during pregnancy including
intrauterine growth restriction, placenta previa, placental
abruption.
Additional outcomes not appropriate for statistical pooling
Data per cycle, per pregnancy or per ET are not appropriate for
pooling because of what statisticians refer to as ’unit of analysis
errors’. Simple group comparison tests for categorical data require
that observations are statistically independent. The use of multiple
observations per woman leads to unpredictable bias in the estimate
of treatment difference Vail 2003. However, due to the frequency
with which this form of data are reported in subfertility research,
we planned to report the following outcomes in narrative form:
• implantation rate, the number of fetal sacs divided by the
number of embryos transferred;
• incidence of miscarriage per total number of pregnancies;
• incidence of multiple pregnancies per total number of
pregnancies.
Search methods for identification of studies
A comprehensive search strategy was developed in consultation
with the Trials Search Co-ordinator of the Cochrane Menstrual
Disorders and Subfertility Group (MDSG). The strategy was used
in an attempt to identify all relevant studies regardless of lan-
guage or publication status (published, unpublished, in press, and
in progress). Relevant trials were identified from both electronic
databases and other resources.
This review will be updated every two years.
Electronic searches
We searched the following electronic databases, from inception to
6 May 2013 with the Cochrane highly sensitive search strategy
for identifying randomised trials, which appears in the Cochrane
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Handbook for Systematic Reviews of Interventions (version 5.1.0;
chapter 6, 6.4.11) (Higgins 2011):
1. The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library latest issue) (see Appendix
1).
2. English language electronic databases: MEDLINE,
EMBASE and PsycINFO (see Appendix 2, Appendix 3,
Appendix 4).
3. The Cochrane Library (www.cochrane.org/index.htm) for
DARE, the Database of Abstracts of Reviews of Effects (reference
lists from non-Cochrane reviews on similar topics).
4. Current Controlled Trials (www.controlled-trials.com).
5. The World Health Organization International Trials
Registry Platform search portal (www.who.int/trialsearch/
Default.aspx).
Searching other resources
We searched the references lists of all included studies and relevant
reviews to identify further relevant articles and when required, we
contacted authors and experts in the relevant field for potential
studies.
We performed a search for grey literature.
Data collection and analysis
We performed statistical analysis in accordance with the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Review Manager 5.1 was used to input data.
Selection of studies
The title, abstract, and keywords of every record retrieved were
scrutinised independently by two review authors (MA, SS) to de-
termine which studies required further assessment. The full texts
were retrieved when the information given in the titles, abstracts,
and keywords suggested that the randomised controlled study in-
tervention was heparin as an adjunct to assisted reproduction ther-
apy.
If there were any doubts regarding these criteria from scanning the
titles and abstracts, the full articles were retrieved for clarification.
Disagreements were resolved by discussion with a third review au-
thor (Professor S Quenby), if necessary. We contacted the authors
of trials to provide missing data, if required.
Data extraction and management
The following informationwas extracted from the studies included
in the review. It is presented in the table ’Characteristics of included
studies’.
Trial characteristics
This includes the following items.
1. Method of generating randomisation sequence.
2. Allocation concealment.
3. Trial design.
4. Number of women screened for eligibility then
randomised, excluded, and finally analysed.
5. Duration, timing, and location of the trial.
6. Source of funding.
Baseline characteristics of the studied groups
1. Age of the women.
2. Duration of infertility.
3. Type of ART.
4. Previous fertility treatments.
Intervention
1. Type of intervention and control group.
2. Dose regimen and timing.
Outcomes
1. Outcomes.
2. How outcomes were defined.
3. How outcomes were measured.
4. Timing of outcome measurement.
All data were extracted independently by two review authors (MA,
SS) using forms designed according to Cochrane guidelines. Addi-
tional information was sought from the authors on trial method-
ology and trial data for trials that appeared to meet the eligibility
criteria but had aspects of methodology that were unclear or where
data were in an unsuitable form for meta-analysis. We planned to
settle any differences of opinion by discussion between the review
authors, but there were no disagreements.
Assessment of risk of bias in included studies
Assessment of risk of bias in the included studies was indepen-
dently performed by two review authors (MA, SS). Disagreements
were noted and resolved by a third review author (SQ).
The ’Risk of bias’ table was included in the Characteristics of
included studies
The following ’Risk of bias’ domainswere assessed according to the
criteria specified by the Cochrane Handbook for Systematic Reviews
of Interventions 5.1.0.
1. Selection bias: Random sequence generation method (e.g.
computer-generated, random number tables, or drawing lots)
and allocation concealment: adequate(e.g. third party, sealed
envelopes); inadequate (e.g. open list of allocation codes); not
clear (e.g. not stated).
2. Performance bias: Blinding of participants and personnel.
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3. Detection bias: Blinding of outcome assessments.
4. Attrition bias: Incomplete outcome data and intention-to-
treat analysis if used.
5. Reporting bias: selective outcome reporting.
6. Other bias: Any other potential sources of bias not included
in this protocol.
Measures of treatment effect
All outcomes were dichotomous. We used the numbers of events
in the control and intervention groups of each study to calculate
odds ratios (OR) with 95% confidence intervals (CI).
Unit of analysis issues
The primary analysis was per woman randomised. Reported data
that did not allowvalid analysis (for example, ’per cycle’ rather than
’per woman’, where women contribute more than one cycle) were
briefly summarised in an additional table and were not used in
meta-analysis. Multiple live births (for example, twins or triplets)
were counted as one live birth event.
Dealing with missing data
The data were analysed on an intention-to-treat basis as far as
possible and attempts were made to obtain missing data from the
original trialists.Where these were unobtainable, only the available
data were analysed.
Assessment of heterogeneity
The review authors (MA, SS) considered whether the participants,
interventions, and outcomes in the included studies were similar
enough to consider pooling in a meta-analysis.
Tests for statistical heterogeneity in pooled data were carried out
using the Chi2 test, with significance set at P < 0.1. The I2 statistic
was used to estimate the total variation across studies that was due
to heterogeneity, where < 25% was considered as low-level, 25%
to 50% as moderate-level, and > 50% as high-level heterogeneity.
If high levels of heterogeneity (I2 > 50%) were seen for primary
outcomes, we explored possible sources of heterogeneity using
sensitivity and subgroup analyses.
Assessment of reporting biases
In view of the difficulty of detecting and correcting for publica-
tion bias and other reporting biases for primary outcomes, we per-
formed a comprehensive search for eligible studies and were alert
for duplication of data. We planned to use a funnel plot to explore
the possibility of small study effects (a tendency for estimates of
the intervention effect to be more beneficial in smaller studies)
if there were 10 or more studies in the primary analysis (Egger
1997).
Data synthesis
Meta-analyses were performed, as appropriate, where data were
available from multiple studies investigating the same treatment
and where the outcomes had been measured in a standard way.
A fixed-effect model was used. We undertook this meta-analysis
according to methods recommended in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). An increase
in the odds of a particular outcome, which may be beneficial (for
example, live birth) or detrimental (for example, adverse effects),
were displayed graphically in the meta-analyses to the right of the
centre-line and a decrease in the odds of an outcome to the left of
the centre-line.
Subgroup analysis and investigation of heterogeneity
If there were sufficient data, we planned to perform the following
subgroup analyses.
1. Efficacy of heparin with different ART excluding IUI.
2. Efficacy of adjunct therapy of heparin with or without
thrombophilia for women undergoing ART.
3. Duration, dose, timing and type of heparin therapy during
ART.
4. Any other adjunct therapy used in addition with heparin
during ART.
5. Efficacy of heparin during ART according to age.
6. Efficacy of heparin with fresh versus frozen ET.
Sensitivity analysis
We performed sensitivity analyses for the primary outcomes to
determine whether the review conclusions would have differed if:
1. eligibility were restricted to studies without high risk of
bias;
2. a random-effects model had been adopted;
3. the summary effect measure had been risk ratio rather than
odds ratio.
Overall quality of the body of evidence: ’Summary of
findings’ table
A ’Summary of findings’ table was generated using GRADEPRO
software. This table evaluated the overall quality of the body of
evidence for main review outcomes, using GRADE criteria (study
limitations (i.e. risk of bias), consistency of effect, imprecision, in-
directness and publication bias). Judgements about evidence qual-
ity (high, moderate or low) were justified, documented, and in-
corporated into reporting of results for main outcomes.
R E S U L T S
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Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Results of the search
Seven studies were identified that assessed the use of peri-implan-
tation heparin in assisted reproduction. Of these only three stud-
ies were eligible for the review. They compared heparin alone
versus either no heparin or placebo. The results of one study
were not published yet, however, the characteristics of that study
(Mashayekhy 2011) are available in ’Characteristics of studies
awaiting classification (completed but not yet published)’. Full
agreement existed between the two researchers, concerning inclu-
sion or exclusion of trials. Figure 1
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Figure 1. Study Review flow diagram.
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Included studies
Three studies Qublan 2008; Urman 2009; Noci 2011 met the
criteria for inclusion in this review. For details see Characteristics
of included studies
Participants
The total number of trial participants was 386. The upper age
limit was < 40 years in all participants in the included studies.
Interventions
All women were included for a single IVF/ICSI (in vitro fertilisa-
tion/intracytoplasmic sperm injection) cycle only. Low molecular
weight heparin (LMWH) was administered from either oocyte re-
trieval or embryo transfer (ET), so the treatment protocol varied
across studies.
In Qublan 2008, LMWH therapy treatment was started from the
day of ET until results of Beta-hCG were available two weeks
after ET. If Beta-hCG was 425 IU/mL, LMWH was continued
either until delivery or foetal demise was diagnosed. In Noci 2011
LMWH treatment was started on the day of oocyte retrieval until
nineweeks of pregnancywith positive pregnancy results. InUrman
2009 LMWH treatment was started a day after oocyte retrieval
until 12 weeks of pregnancy with positive pregnancy test results.
Control groups in these studies received placebo (Qublan 2008)
or no heparin (Urman 2009; Noci 2011)
Outcomes
All three included studies reported live birth rate per woman as
the primary outcome, adverse effects, clinical pregnancy rate per
woman, multiple pregnancy rate per woman, implantation rate
per woman and miscarriage rate per woman.
Additional outcomes not appropriate for statistical pooling
Data per cycle, per pregnancy or per ET were not appropriate for
pooling. We have reported the following in additional tables:
• implantation rate, the number of fetal sacs divided by the
number of embryos transferred; Table 1
• incidence of miscarriage per total number of pregnancies;
Table 2
• incidence of multiple pregnancies per total number of
pregnancies; Table 3
Excluded studies
Three studies failed to meet the inclusion criteria. Colicchia 2011
was excluded because LMWHwas used in conjunction with pred-
nisolone. Stern 2003 was excluded because unfractionated hep-
arin (UFH) was used in conjunction with low-dose aspirin. Berker
2011 was excluded because it was a quasi-randomised study. De-
tails are provided in Characteristics of excluded studies.
Risk of bias in included studies
The methodological quality of included studies was documented
in the ’Risk of bias’ table for each individual study. The ’Risk of
bias’ summary and ’Risk of bias’ graph are presented as Figure 2
and Figure 3.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
All three studies were rated as at low risk of this bias.
Allocation concealment
Two studies were rated as at low risk of this bias (Noci 2011;
Urman 2009). The third study was rated as at unclear risk, as
concealment of allocation was not described Qublan 2008.
Blinding
Fertility outcomes
One of the studies described use of placebo (Qublan 2008) and
was rated as at low risk of performance bias for fertility outcomes.
Neither of the other studies described blinding of participants.
However we considered that blinding was unlikely to influence
fertility outcomes, sowe rated these two studies as at unclear risk of
performance bias for these outcomes. One study reported blinded
assessment of fertility outcomes (Noci 2011) and we rated it as at
low risk of detection bias. The other two studies were rated as at
unclear risk of detection bias for fertility outcomes.
Adverse events
Lack of blinding may influence reporting of adverse events. The
study using placebo (Qublan 2008) was rated as at low risk of
performance bias for adverse events, but the other two studies
were rated as at high risk. None of the studies reported blinded
assessment of adverse events and we rated all studies as at high risk
of detection bias for this outcome.
Incomplete outcome data
In Qublan 2008 the reporting in the trial publication was incon-
sistent. It was stated that 137 women were randomised but sub-
sequently stated that 83 were randomised. All 83 were included
in analysis. The study was rated as at unclear risk of bias in this
domain.
In Urman 2009, 153 women were recruited to the trial. Three
women in the treatment and control groups were lost to follow-
up before completion of initial follow-up (completion of the 20th
gestational week for the latest recruited participant who achieved
an ongoing pregnancy), and another two women in the LMWH
group were lost to follow-up after completion of the 20th ges-
tational week but before delivery or expected completion of the
40th gestational week. Women lost to follow-up during the first
period were considered not to have an ongoing pregnancy, and
women lost to follow-up in the second period were considered not
to have a live birth in the intention-to-treat analysis. The dropout
rate was 5.22%. In the final analysis, 75 women in each group
were considered. The study was rated as at low risk of attrition bias
because trialists compensated for dropouts by imputing a negative
outcome to losses to follow-up.
Noci 2011 enrolled 210 patients presenting all the necessary re-
quirements and subjected to ovarian stimulation for IVF/ICSI.
On the day of oocyte retrieval, 38 patients were excluded: 30 for
the absence of retrieved oocytes or cancelled cycles and eight who
decided to decline their participation. One hundred and seventy-
two women were allocated to intervention and divided into two
groups: 86women in the control group and 86women in the treat-
ment group. The final series for analysis contained 153 women be-
cause 13 women belonging to the treatment group and six women
belonging to the control group had no embryos to transfer, thus
they were immediately excluded from the study. Thus in the final
analysis, 73 women were in treatment group and 80 women were
in the control group. The dropout rate was 8.72% after allocation
to the intervention. The study was rated as at unclear risk of attri-
tion bias.
Selective reporting
None of the studies reported comparative data on adverse events
and so all were rated as at unclear risk of bias in this domain.
Other potential sources of bias
No other potential sources of bias were identified in any of the
included studies, and all were rated as at low risk of bias in this
domain.
Effects of interventions
See: Summary of findings for the main comparison Heparin
for Assisted Reproduction (fixed effect); Summary of findings 2
Heparin for Assisted Reproduction (random effects)
Primary Outcomes
1. Live birth rate per woman
All three included studies assessed the primary outcome, namely
’live birth rate per woman’.
Results pooled in meta-analysis (fixed-effect model) showed that
there was a significant improvement in live birth rate with the
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use of LMWH (odds ratio (OR)1.77, 95% confidence interval
(CI) 1.07, 2.90 P = 0.03, I2 = 51%, three studies, 386 women)
in comparison to placebo or no LMWH (Figure 4). Sensitivity
analysis performedwith a random-effects model showed that there
was a non significant improvement in live birth rate with the use
of LMWH compared to no LMWH (OR1.85, 95%CI 0.80, 4.24
P,=,0.15, I2,=,51%, three studies, 386 women)
Figure 4. Forest plot of comparison: 1 Heparin versus control, outcome: 1.1 Live Birth Rate per woman.
This finding should be viewed with extreme caution due to high
heterogeneity and sensitivity to choice of statistical model.
The evidence was of very low quality as shown in Summary of
findings for the main comparison.
2. Adverse effects
Direct adverse effects of heparin including bleeding, bruising,
thrombocytopenia or any other side effects were described in all
the included studies.
Qublan 2008 reported that the most frequent complications
encountered in the heparin-treated group were bleeding (3/42,
7.1%) followed by thrombocytopenia (2/42, 4.8%) and allergic
reactions (1/42, 2.4%).
Urman 2009 reported that platelet counts did not change signif-
icantly in the LMWH group during the study period and that
none of the participants experienced any adverse effects other than
small ecchymosis around the LMWH injection sites. None of the
participants in the LMWH group discontinued treatment due to
pain or ecchymosis around the injection site. It was unclear to
what extent adverse effects in the control group were assessed.
Noci 2011 reported no other adverse effects in the study except
minimal bruising at injection site of heparin.
It appeared from the studies that longer duration of heparin ther-
apy increased the number of side effects; however this interpreta-
tion must be looked with caution as there was no available con-
trolled comparative data for duration of therapy.
In Qublan 2008 LMWH therapy was started from the day of ET
until results of Beta-hCG were available two weeks after ET. If
Beta-hCG was 425 IU/mL, LMWH was continued either until
delivery or foetal demise was diagnosed. In Noci 2011, LMWH
treatment was started on the day of oocyte retrieval until nine
weeks of pregnancy with positive pregnancy results. In Urman
2009 LMWH treatment was started a day after oocyte retrieval
until 12 weeks of pregnancy with positive pregnancy test results.
Secondary Outcomes
1. Clinical pregnancy rates per woman
‘Clinical pregnancy rate per woman’ was described in all included
studies.
Results pooled in meta-analysis (fixed-effect model) showed a sig-
nificant improvement in clinical pregnancy rate with the use of
LMWH compared with placebo or no LMWH (OR 1.61 95%
CI 1.03, 2.53 P = 0.04, I2 = 29%, three studies, 368 women)
Figure 5. Sensitivity analysis performed with a random-effects
model showed no significant improvement in clinical pregnancy
rate with the use of LMWH compared to no LMWH (OR 1.66,
95% CI 0.94 to 2.90, I2 = 29%, three studies, 368 women).
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Figure 5. Forest plot of comparison: 1 Heparin versus control, outcome: 1.3 Clinical Pregnancy Rate per
woman.
These results should be viewed with caution due to high hetero-
geneity and sensitivity to choice of statistical model.
The evidence is of very low quality, as shown in Summary of
findings for the main comparison.
2. Multiple pregnancy rates per woman
‘Multiple pregnancy rates per woman’ were not reported in any of
the included studies. “Multiple pregnancy rates per total number
of pregnancies” was reported in all studies but cannot be pooled
for meta-analysis due to unit of analysis errors. Please see Table 3
3. Maternal pregnancy complications
Qublan 2008 reported placental abruption (1/42, 2.4%) in
LMWH group. Two (4.9%) women in the placebo group devel-
oped pre-eclampsia.
Urman 2009 reported that total numbers of preterm deliveries
were nine (34.6%) in LMWH and six (30.0%) in control groups
(P = 0.74). Three women delivered in the 32nd week (one set
of quadruplets, one set of twins and a singleton, all in LMWH
group), one woman (singleton in control group) delivered in the
33rd week, four women delivered in the 34th week (two sets of
twins in LMWHgroup and two sets of twins in the control group),
four women delivered in the 35th week (all twins, three and one
in LMWH and control groups, respectively) and three women
delivered in the 36th week (one singleton in LMWH group and
two sets of twins in the control group).
Noci 2011 did not describe any maternal pregnancy complica-
tions.
4. Fetal complications during pregnancy
Qublan 2008 reported two intrauterine foetal deaths in the hep-
arin-treated group compared to none in the control group. No
further details were provided.
Urman 2009 reported that none of the infants delivered in the
study had any congenital malformations. One boy (from the
LMWH group) had a unilateral undescended testis, and another
infant delivered at the 32nd week (from the LMWH group) un-
derwent surgery due to necrotising enterocolitis.
Noci 2011 did not describe any fetal complications during preg-
nancy.
Other analyses
There were insufficient studies to conduct the planned subgroup
analyses or to construct a funnel plot to assess publication bias.
We considered clinical and methodological differences between
the studies that might account for the high heterogeneity in the
analysis of live birth. Exclusion of the study that was clearly re-
stricted to women with at least one thrombophilic defect (Qublan
2008) eliminated the heterogeneity (I2 = 0%). However, with so
few studies available for analysis it is unclear whether the effects
of the intervention may differ in this population.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Heparin for assisted reproduction
Population: Subfertile women
Settings: Assisted reproduction treatment (ART)
Intervention: Heparin versus placebo or no heparin
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI) using a random
effects model
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Heparin
Live birth rate per
woman
173 per 1000 280 per 1000
(144 to 471)
OR 1.85
(0.8 to 4.24)
386
(3 studies)
⊕©©©
very low1,2
Estimate using a fixed ef-
fect model: OR 1.77, 95%
CI 1.07 to 2.9
Clinical pregnancy rate
per woman
250 per 1000 356 per 1000
(239 to 492)
OR 1.66
(0.94 to 2.9)
386
(3 studies)
⊕©©©
low2
Estimate using a fixed ef-
fect model: OR 1.61 95%
CI 1.03 to 2.53
Adverse effects No comparative data available so no conclusions could be drawn. Adverse effects such as bleeding and thrombocytopenia were reported in the heparin groups
and affected 5-7% of women in one study
*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Inconsistency (high heterogeneity: I2=51%)
2 Imprecision: low overall event rate, confidence intervals compatible with substantial benefit or no appreciable benefit, findings sensitive
to choice of statistical model.1
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D I S C U S S I O N
Summary of main results
The aim of this review was to investigate whether the administra-
tion of heparin during the peri-implantation period improves clin-
ical outcomes in subfertile women undergoing assisted reproduc-
tion. We found evidence suggesting that administration of peri-
implantation low molecular weight heparin (LMWH) may im-
prove live birth and pregnancy rates during assisted reproduction,
however the studies were few and small (three studies, total 386
participating women) with high heterogeneity and sensitivity to
choice of statisticalmodel. Therefore all resultsmust be interpreted
with extreme caution.
Low molecular weight heparin was associated with adverse events,
including bruising, ecchymosis, bleeding, thrombocytopenia and
allergic reactions. There was a suggestion that adverse effects in-
creased if heparin therapy was used over a longer duration. There
were no reliable data on long-term side effects of heparin at this
stage of pregnancy.
Overall, this evidence does not justify the present widespread use
of LMWH in this population subgroup (previous failed IVF),
outside well-conducted randomised trials. Such trials should be a
priority.
Overall completeness and applicability of
evidence
There were only three studies that could be included in the review
and the total sample size was small (386 women) so the findings
have to be viewed with caution. Moreover, study characteristics
varied: one was a multicentre study Noci 2011 while the two
others were conducted at a single centre (Qublan 2008; Urman
2009). There was no uniformity of dose, timing or duration of the
intervention. Only one study Qublan 2008 used sodium chloride
as placebo control, the other two included studies had no placebo,
hence the patients were not blinded. Furthermore, none of the
studies described blinding of clinicians.
Wewere unable to adequately assess the effect of heparin inwomen
with or without thrombophilia undergoing assisted reproduction
as only one study (Qublan 2008) included women with throm-
bophilia, Noci 2011 included women without thrombophilia, the
other remaining study (Urman 2009), did not report about the
presence or absence of thrombophilia in including participants.
The small numbers of underpowered trials means that there was
insufficient evidence to change clinical practice until results of large
high quality randomised controlled trials (RCTs) are available.
Quality of the evidence
The main limitations of individual studies were small sample size,
failure to report blinded comparative data on adverse events and (in
one case) failure to describe allocation concealment.When studies
were combined there was high heterogeneity for the analysis of live
birth, and findings for both live birth and clinical pregnancy were
sensitive to choice of statistical model. The quality of the evidence
for live birth and clinical pregnancy was rated as very low and low
(respectively), using GRADE criteria (Summary of findings for
the main comparison).
Potential biases in the review process
The findings were sensitive to methodological decisions made in
the review process, and are therefore to be regarded very cautiously.
Agreements and disagreements with other
studies or reviews
It has been suggested that heparin could potentially modulate
many of the known mechanisms that underlie successful apposi-
tion, adhesion and penetration of the developing embryo.Heparin
could improve the endometrial environment for implantation of
embryo. Confirmation of the outlined potential of heparin to al-
ter the molecular processes underpinning successful implantation
was urgently required given the potential for clinical translation to
increased pregnancy and live birth rate and a reduction in adverse
perinatal outcomes for all women undergoing assisted reproduc-
tion (Nelson 2008).The following studies showed no efficacy of
heparin in improving outcome.
• In one small non-randomised study, heparin with low-dose
aspirin was given to women with antiphospholipid positive
antibodies undergoing assisted reproduction. There were no
statistically significant differences detected in implantation,
pregnancy and ongoing pregnancy rates between both groups
(Kutteh 1997).
• A double-blind, randomised cross-over trial was conducted
to investigate whether heparin and low-dose aspirin increase the
pregnancy rate in antiphospholipid antibody or antinuclear
antibody-seropositive women with IVF implantation failure.
Unfractionated heparin and low-dose aspirin were given from
day of embryo transfer. It found that there was no significant
difference in pregnancy rates or implantation rates between
treated and placebo cycles. However, a cross-over design is not
appropriate for a pregnancy trial (Stern 2003).
• Heparin was given to women with thrombophilia and
repeated implantation failure undergoing assisted reproduction
in this prospective cohort study. Authors suggested that it
showed improvement in biochemical and clinical pregnancy
rates. However, no precise data were published. This study also
looked at other factors of implantation failure, therefore it
cannot be inferred that this intervention of heparin only
improved the success rate of assisted reproduction (Sharif 2010).
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The American Society for Reproductive Medicine (Practice
Committee of ASRM 2008) assessed available data in 2008 and
suggested that assessment of antiphospholipid antibodies was not
indicated among couples undergoing IVF, and heparin therapy
was not justifiable on the basis of existing data to improve preg-
nancy and live birth rates.
In agreement with our review, Ricci 2010 suggested that heparin
should not be used in women undergoing IVF until its efficacy is
demonstrated in carefully designed RCTs.
Three published studies suggested that heparin did improve clin-
ical outcome:
• One single centre non-randomised study found that
heparin with low-dose aspirin given to women undergoing
assisted reproduction with positive antiphospholipid antibodies
showed improvement in live birth rate and clinical pregnancy
rate Sher 1994.
• The same results were shown by a single centre case control
study by the same author Sher 1998. However, these studies are
non-randomised and significant bias was found.
• Lodigiani 2011 presented observational retrospective
analysis of women with previous implantation failure and
screened for thrombophilia undergoing assisted reproduction
who were given LMWH showed significantly higher pregnancy
rates. The results also showed that there was no relation between
inherited thrombophilia and pregnancy rate in patients with
previous IVF implantation failures. This was an observational
retrospective study, which could be influenced by various other
factors.
We found two reviews on this topic which also agree with our
conclusions:
• Nardo 2009 suggested that clinicians should inform
patients of factors including: our current lack of knowledge;
potential adverse effects; and available weak evidence regarding
adjuvant therapy during assisted reproduction. There was need
for good clinical trials in many of the areas surrounding medical
adjuncts in IVF to resolve the empirical/evidence divide.
• Bohlmann 2011 suggested that the available studies on
heparin in assisted reproduction were characterised by
heterogeneous inclusion criteria and a lack of proven
effectiveness in special constellations. In conclusion, the
application of heparin to improve assisted reproduction
treatment (ART) outcome rates was not justified. A large RCT
should be undertaken to answer this.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
It is unclear whether peri-implantation heparin in assisted repro-
duction treatment (ART) cycles improves live birth and clinical
pregnancy rates in subfertile women, as the evidence was sensitive
to choice of statistical model and no benefit was apparent when
a random effects model was used. Side effects have been reported
with use of heparin and no firm conclusions can be drawn regard-
ing its safety. Our results do not justify the use of heparin in this
context, except in well-conducted research trials.
Implications for research
Well-designed RCTs with sufficient power are warranted to assess
the efficacy of peri-implantation heparin in improving assisted re-
production outcomes. These should be large parallel-group RCTs
with populations of subfertile women with unexplained infertil-
ity, recurrent failure of embryo implantation or a positive throm-
bophilia screen. No additional adjunct therapies should be used.
Cross-over designs should always be avoided in trials where preg-
nancy is an intended outcome.
Studies should report data on adverse events in both study groups.
Studies should be done where local (uterine) rather than systemic
heparin is used to see the effects of heparin on decidualisation,
implantation and pregnancy rates in an attempt to avoid adverse
effects.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Noci 2011
Methods Multicentre
Prospective randomised control pilot study
Participants 172 patients were allocated to intervention and divided into two groups: 86 women in
the control group and 86 women in the treatment group. The final series for analysis
contained 153 patients because 13 women belonging to treatment group and 6 women
belonging to the control group had no embryos to transfer, thus they were immediately
excluded from the study
So in the final analysis 73 women were in treatment group (A) and 80 women were in
the control group (B). Both groups were matched. Every woman was recruited for only
one cycle. Cause infertility: variety of causes
Interventions IVF or ICSI. The treatment group (A) received both luteal phase support with vaginal
progesterone (Prometrium 200 mg twice per day) and a prophylactic dose of dalteparin
sodium (Fragmin, 2500 IU s.c. daily; Pfizer Italia, Latina, Italy) from the afternoon
of the day of oocyte retrieval until the day of pregnancy test. The control group (B)
received luteal phase support with progesterone only until pregnancy test. Platelet count
was performed on days7-8 of dalteparin treatment to evaluate possible adverse effects
of the therapy. If platelet values dropped to below 50% of basal levels or <100,000/
µL, dalteparin administration was immediately stopped because of the risk of heparin
induced thrombocytopenia
COH: FSH, GNRH analogue. HCG 250 mcg. Luteal support: progesterone 200 mg
pessaries vaginally twice daily until a pregnancy test was performed. If the test was
positive, progesterone treatment was continued up to 12 gestational weeks
Outcomes Live birth rate per woman: LMWH group (A): 21%, Control group (B): 16 %
Adverse effect: Thrombocytopenia was not observed in any of the 73 patients treated
with dalteparin and only a few patients reported the presence of minimal bruising at the
injection point of the drug
Clinical pregnancy rate per woman: LMWH group (A): 26%, Control group (B): 20%
Multiple pregnancy rate per woman: LMWH group (A): 31.57%, Control group (B):
12.5%
Implantation rate/ embryo transferred LMWH group (A): 15%Control group (B): 12%
Spontaneous Miscarriage rate per woman: LMWH group (A): 21%, Control group (B)
: 19%
Notes Study population consisted of women aged < 40years, without congenital or acquired
thrombophilia and undergoing their first IVF cycle
Risk of bias
Bias Authors’ judgement Support for judgement
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Noci 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Computerised random sequence genera-
tion method was used
Allocation concealment (selection bias) Low risk Described clearly with sealed and num-
bered envelopes containing the allocation
information
Blinding of participants and personnel for
fertility outcomes
Unclear risk Not described, but unclear whether lack of
blinding could influence outcome
Blinding of outcome assessment for fertility
outcomes
Low risk The ultrasonography was performed by a
gynaecologist unaware of the allocation of
the patients
Blinding of participants and personnel for
adverse effects outcome
High risk Not described and lack of blinding could
influence outcome
Blinding of outcome assessment for adverse
effects outcome
High risk Not described and lack of blinding could
influence outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study had a follow-up rate of 89%
(153/172 women included in analysis)
Selective reporting (reporting bias) Unclear risk Describes selected adverse effects in inter-
vention group, but no comparative data on
adverse effects was reported
Other bias Low risk No other potential bias identified
Qublan 2008
Methods Single centre
Prospective randomised placebo controlled
Participants States that of 137 women with a history of three or more previous IVF failures and who
had at least one thrombophilic defect, adn who were randomised to heparin or placebo,
39 did not meet the inclusion criteria and 15 refused participation. The remaining 83
women were randomly allocated to each arm of the study. Randomisation was started
on the day of ET
Interventions The treatment group (A) (n = 42) had enoxaparin 40 mg/day subcutaneous injections.
Control Group (B) (n = 41) received placebo (equivalent volume of NaCl 0.9% sub-
cutaneous; Pharmaceutical Solutions Industry Ltd., Jeddah, SA). Treatment was started
from the day of ET until results of Beta-hCG were available 2 weeks after ET. If Beta-
hCG was 425 IU/mL, LMWH was continued either until delivery or foetal demise was
diagnosed
COH: HMG, GNRH antagonist. HCG 10,000 IU. Luteal support: Progesterone pes-
saries (Cyclogest: Alpharma, Barnstaple, UK) were used for luteal phase support in the
25Heparin for assisted reproduction (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Qublan 2008 (Continued)
two study groups
Outcomes Live birth rate per woman: LMWH group (A): 23.8%, Control group (B): 2.4%
Adverse effect: The frequency of complications did not differ between the two study
groups. Themost frequent complications encountered in the heparin-treated were bleed-
ing (7.1%) followed by thrombocytopenia (4.8%), allergic reactions (2.4%) and placen-
tal abruption (2.4%)
Pregnancy rate per woman: LMWH group (A): 31%, Control group (B): 9.6%
Multiple pregnancy rate per woman: LMWH group (A): 23.1%, Control group (B):
25%
Implantation rate/ embryo transferred LMWH group (A): 19.8% Control group (B): 6.
1%
Spontaneous Miscarriage rate per woman: LMWH group (A): 7.7%, Control group (B)
: 50%
Intrauterine Fetal death rate: LMWH group (A) 15.4%, control group 0%
Notes Study population consisted of women aged 19-35 years with a history of three or more
previous IVF failures, and who had at least one thrombophilic defect
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation was done by selection from table
of random numbers
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel for
fertility outcomes
Low risk Placebo used. States “only the subjects were
blinded to the intervention” (Moreover it
is unclear whether lack of blinding could
influence this outcome)
Blinding of outcome assessment for fertility
outcomes
Unclear risk Not described, but unclear whether lack of
blinding could influence outcome
Blinding of participants and personnel for
adverse effects outcome
Low risk Placebo used (equivalent volume of nor-
mal saline). States “only the subjects were
blinded to the intervention”
Blinding of outcome assessment for adverse
effects outcome
High risk Not described and lack of blinding could
influence outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reporting in trial publication is inconsis-
tent. States that 137 women were ran-
domised and subsequently states that 83
were randomised
26Heparin for assisted reproduction (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Qublan 2008 (Continued)
Selective reporting (reporting bias) Unclear risk Describes “most frequent” complications
in each group, but no comparative data on
adverse effects was reported
Other bias Low risk No other potential bias identified
Urman 2009
Methods Single centre
Open labelled randomised controlled pilot trial
Participants 150 consecutive couples who met the inclusion criteria and gave informed consent were
recruited to the trial. Each woman was included for one cycle only. 3 women in the
LMWH and control group each were lost to follow-up before completion of the initially
planned follow-upperiod (completionof the 20th gestational week for the latest recruited
participant that achieved an ongoing pregnancy), and another 2 women in the LMWH
group were lost to follow-up after completion of the 20th gestational week but before
delivery or expected completion of the 40th gestational week. 75 women in each arm of
the study
Interventions ICSI. The study group was administered LMWH group (A) (Enoxaparin Sodium,
Clexane, Aventis Pharma) at a dose of 1 mg/kg/day starting on the day after oocyte
retrieval. Patients’ weights were rounded to the closest multiple of 10 kg, and 0.1 mL/10
kg/day Clexane was self-administered subcutaneously by the participants. LMWH was
discontinued if the pregnancy test 12 days after ET was negative, but continued up to
the 12th week of pregnancy if the test was positive. The control group (B) received no
medication besides progesterone gel. In the study group the platelet count was done on
the day of oocyte retrieval and 1 week after commencement of LMWH treatment
COH: FSH, GNRH agonist. HCG 10,000 IU. Luteal support: Progesterone pessaries
90 mg vaginal progesterone gel (Crinone 8%, Serono, Serono, Bedfordshire, UK) start-
ing from the day of oocyte collection. LPS was continued until the pregnancy test per-
formed 12 days after ET. Women with a positive pregnancy test continued the vaginal
progesterone gel until the 12th week of gestation
Outcomes Live birth rate per woman: LMWH group (A): 34.7%, Control group (B): 26.7%
Adverse effect: Platelet counts did not change significantly in the LMWH group during
the study period. Small ecchymoses around the LMWH injection sites were noted
Clinical Pregnancy rate per woman: LMWH group (A): 45.3%, Control group (B): 38.
7%
Ongoing Pregnancy rate per woman: LMWH group (A): 37.3%, Control group (B):
26.7%
Multiple pregnancy rate per woman: LMWH group (A): 35.3%, Control group (B): 34.
5%
Implantation rate/ embryo transferred LMWH group (A): 24.5% Control group (B):
19.8%
Numbers of preterm deliveries were (34.6%) in LMWH and (30.0%) in control groups
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Urman 2009 (Continued)
Notes Study population consisted of women aged < 38 years with a history of two or more
previous IVF failures. Women lost to follow-up during the first period were considered
not to have an ongoing pregnancy, and women lost to follow-up in the second period
were considered not to have a live birth in the intention-to-treat analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Women were randomised according to
a computer-generated randomisation list.
Study subjects were randomised in blocks
of 10; i.e. of every 10 women randomised,
five were allocated to the LMWH arm, and
five were allocated to the control arm, in a
random manner
Allocation concealment (selection bias) Low risk Opaque envelopes that were numbered and
sealed containing the allocation informa-
tion were given to the ART centre nurse
coordinator who assigned patients to study
arms following recruitment by attending
physicians on the morning of oocyte re-
trieval procedure
Blinding of participants and personnel for
fertility outcomes
Unclear risk Open label but unclear whether lack of
blinding could influence outcome
Blinding of outcome assessment for fertility
outcomes
Unclear risk Open label, but unclear whether lack of
blinding could influence outcome
Blinding of participants and personnel for
adverse effects outcome
High risk Open label and lack of blinding could in-
fluence outcome
Blinding of outcome assessment for adverse
effects outcome
High risk Open label and lack of blinding could in-
fluence outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk This study compensated for dropouts by
imputing a negative outcome to losses to
follow-up
Selective reporting (reporting bias) Unclear risk Adverse effects in the intervention group
were described but it was unclear to what
extent adverse effects in the control group
were assessed and no clear comparative data
were reported
Other bias Low risk No other potential bias identified
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COH: controlled ovarian hyperstimulation
ET: embryo transfer
FSH: follicle-stimulating hormone
GNRH: gonadotropin-releasing hormone
HCG: human chorionic gonadotropin
ICSI: intracytoplasmic sperm injection
IVF: in vitro fertilisation
IU: international units
LMWH: low molecular weight heparin
LPS: lipopolysaccharide,
NaCl: sodium chloride
s.c.: subcutaneous
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Berker 2011 Not a True RCT as quasi randomisation was performed for the purposes of this study
Colicchia 2011 Low molecular weight heparin (LMWH) was used in conjunction with prednisolone
Stern 2003 Unfractionated heparin (UFH) was used in conjunction with low-dose aspirin. Cross-over design study
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Mashayekhy 2011
Methods Single centre
Prospective randomised controlled trial
Participants 86 patients with recurrent IVF-ET failure.
Interventions Ovarian stimulation was performed with long protocol. The patients were randomly divided into two groups after
embryo transfer, and one group received unfractionated heparin 5000 IU twice a day plus 100 mg progesterone and
another group only received progesterone
Outcomes There were no significant differences between individual characteristics of two groups. However, implantation rate
and clinical pregnancy were significantly higher in patients who received unfractionated heparin. Thirty-six women
had at least one thrombophilic mutation
Notes Only the abstract has been published in The Iranian Journal of Reproductive Medicine spring 2011;9 (Suppl 2):30-
30
The authors were contacted regarding the details of study results. The study is presently not able to be included in
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Mashayekhy 2011 (Continued)
the review as it has been completed and submitted for publication. The authors were unable to provide me with the
details of results till publication
ET: embryo transfer
IU: international units
IVF: iv vitro fertilisation
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D A T A A N D A N A L Y S E S
Comparison 1. Heparin versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live Birth Rate per woman 3 386 Odds Ratio (M-H, Fixed, 95% CI) 1.77 [1.07, 2.90]
2 Sens analysis Live Birth Rate
(random effects)
3 386 Odds Ratio (M-H, Random, 95% CI) 1.85 [0.80, 4.24]
3 Clinical Pregnancy Rate per
woman
3 386 Odds Ratio (M-H, Fixed, 95% CI) 1.61 [1.03, 2.53]
4 Sens analysis Clinical Pregnancy
Rate (random effects)
3 386 Odds Ratio (M-H, Random, 95% CI) 1.66 [0.94, 2.90]
Analysis 1.1. Comparison 1 Heparin versus control, Outcome 1 Live Birth Rate per woman.
Review: Heparin for assisted reproduction
Comparison: 1 Heparin versus control
Outcome: 1 Live Birth Rate per woman
Study or subgroup Heparin Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Noci 2011 15/73 13/80 41.6 % 1.33 [ 0.59, 3.03 ]
Qublan 2008 10/42 1/41 3.3 % 12.50 [ 1.52, 102.85 ]
Urman 2009 26/75 20/75 55.1 % 1.46 [ 0.73, 2.93 ]
Total (95% CI) 190 196 100.0 % 1.77 [ 1.07, 2.90 ]
Total events: 51 (Heparin), 34 (Control)
Heterogeneity: Chi2 = 4.05, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 2.24 (P = 0.025)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Control Favours Heparin
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Analysis 1.2. Comparison 1 Heparin versus control, Outcome 2 Sens analysis Live Birth Rate (random
effects).
Review: Heparin for assisted reproduction
Comparison: 1 Heparin versus control
Outcome: 2 Sens analysis Live Birth Rate (random effects)
Study or subgroup Heparin Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Noci 2011 15/73 13/80 41.1 % 1.33 [ 0.59, 3.03 ]
Qublan 2008 10/42 1/41 12.7 % 12.50 [ 1.52, 102.85 ]
Urman 2009 26/75 20/75 46.2 % 1.46 [ 0.73, 2.93 ]
Total (95% CI) 190 196 100.0 % 1.85 [ 0.80, 4.24 ]
Total events: 51 (Heparin), 34 (Control)
Heterogeneity: Tau2 = 0.26; Chi2 = 4.05, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Control Favours Heparin
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Analysis 1.3. Comparison 1 Heparin versus control, Outcome 3 Clinical Pregnancy Rate per woman.
Review: Heparin for assisted reproduction
Comparison: 1 Heparin versus control
Outcome: 3 Clinical Pregnancy Rate per woman
Study or subgroup Heparin Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Noci 2011 19/73 16/80 37.7 % 1.41 [ 0.66, 3.00 ]
Qublan 2008 13/42 4/41 9.3 % 4.15 [ 1.22, 14.07 ]
Urman 2009 34/75 29/75 52.9 % 1.32 [ 0.69, 2.52 ]
Total (95% CI) 190 196 100.0 % 1.61 [ 1.03, 2.53 ]
Total events: 66 (Heparin), 49 (Control)
Heterogeneity: Chi2 = 2.80, df = 2 (P = 0.25); I2 =29%
Test for overall effect: Z = 2.08 (P = 0.037)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Control Favours Heparin
Analysis 1.4. Comparison 1 Heparin versus control, Outcome 4 Sens analysis Clinical Pregnancy Rate
(random effects).
Review: Heparin for assisted reproduction
Comparison: 1 Heparin versus control
Outcome: 4 Sens analysis Clinical Pregnancy Rate (random effects)
Study or subgroup Heparin Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Noci 2011 19/73 16/80 37.1 % 1.41 [ 0.66, 3.00 ]
Qublan 2008 13/42 4/41 17.8 % 4.15 [ 1.22, 14.07 ]
Urman 2009 34/75 29/75 45.1 % 1.32 [ 0.69, 2.52 ]
Total (95% CI) 190 196 100.0 % 1.66 [ 0.94, 2.90 ]
Total events: 66 (Heparin), 49 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 2.80, df = 2 (P = 0.25); I2 =29%
Test for overall effect: Z = 1.76 (P = 0.079)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Control Favours Heparin
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A D D I T I O N A L T A B L E S
Table 1. Table of Comparisons: Implantation rate per embryos transferred
Study ID Heparin group Control group
Noci 2011 15% 12%
Urman 2009 24.5% 19.8%
Qublan 2008 19.8% 6.1%
Table 2. Table of Comparisons: Incidence of miscarriage per total number of pregnancies and per woman
Study ID Heparin group per
pregnancy
Control group per
pregnancy
Heparin group per woman Control group per woman
Noci 2011 4/19 3/16 4/73 3/80
Urman 2009 n/a n/a n/a n/a
Qublan 2008 1/13
*IUFD 2/13
2/4
*IUFD 0/4
1/42
*IUFD 2/42
2/41
*IUFD 0/41
IUFD: Intraunterine fetal death
Table 3. Table of Comparisons: Incidence of multiple pregnancies per total number of pregnancies
Study ID Heparin group Control group
Noci 2011 (6/19) 31.5% (2/16) 12.5%
Urman 2009 (12/34) 35.3% (10/29) 34.5%
Qublan 2008 (3/13) 23.1% (1/4) 25%
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
Menstrual Disorders and Subfertility Group Specialised Register (inception to 2 July 2012)
Ovid the Cochrane Central Register of Controlled Trials (CENTRAL) (inception to 2 July 2012)
There is no language restriction in these search.
1 exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/
2 embryo transfer$.tw.
3 in vitro fertilisation.tw.
4 ivf-et.tw.
5 (ivf or et).tw.
6 icsi.tw.
7 intracytoplasmic sperm injection$.tw.
8 (blastocyst adj2 transfer$).tw.
9 (assist$ adj2 reproducti$).tw.
10 exp insemination, artificial/ or exp reproductive techniques, assisted/
11 artificial$ inseminat$.tw.
12 iui.tw.
13 intrauterine insemination.tw.
14 nidation.tw.
15 reproductive technique$.tw.
16 reproduct$ technolog$.tw.
17 exp Embryo Implantation/
18 (implant$ adj2 fail$).tw.
19 reproduct$ technique$.tw.
20 exp Infertility, Female/
21 ((Female$ or women) adj2 infertil$).tw.
22 ((Female$ or women) adj2 subfertil$).tw.
23 exp Abortion, Habitual/
24 recurrent miscarriage$.tw.
25 or/1-24 (8324)
26 exp heparin/ or exp heparin, low-molecular-weight/ or exp heparinoids/
27 heparin$.tw.
28 LMWH$.tw.
29 liquemin.tw.
30 enoxaparin.tw.
31 heparinic acid.tw.
32 dalteparin.tw.
33 tinzaparin.tw.
34 clexane.tw.
35 lovenox.tw.
36 indenox.tw.
37 xaparin.tw.
38 or/26-37
39 25 and 38
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Appendix 2. MEDLINE search strategy
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) (1950 to
2 July 2012)
TheMEDLINE search was combined with the Cochrane highly sensitive search strategy for identifying randomized trials which
appears in the Cochrane Handbook of Systematic Reviews of Interventions (version 5.0.2; chapter 6, 6.4.11)
There is no language restriction in this search
1 exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/
2 embryo transfer$.tw.
3 in vitro fertilisation.tw.
4 ivf-et.tw.
5 (ivf or et).tw.
6 icsi.tw.
7 intracytoplasmic sperm injection$.tw.
8 (blastocyst adj2 transfer$).tw.
9 (assist$ adj2 reproducti$).tw.
10 exp insemination, artificial/ or exp reproductive techniques, assisted/
11 artificial$ inseminat$.tw.
12 iui.tw.
13 intrauterine insemination.tw.
14 nidation.tw.
15 reproductive technique$.tw.
16 reproduct$ technolog$.tw.
17 exp Embryo Implantation/
18 (implant$ adj2 fail$).tw.
19 reproduct$ technique$.tw.
20 exp Infertility, Female/
21 ((Female$ or women) adj2 infertil$).tw.
22 ((Female$ or women) adj2 subfertil$).tw.
23 exp Abortion, Habitual/
24 recurrent miscarriage$.tw.
25 or/1-24
26 exp heparin/ or exp heparin, low-molecular-weight/ or exp heparinoids/
27 heparin$.tw.
28 LMWH$.tw.
29 liquemin.tw.
30 enoxaparin.tw.
31 heparinic acid.tw.
32 dalteparin.tw.
33 tinzaparin.tw.
34 clexane.tw.
35 lovenox.tw.
36 indenox.tw.
37 xaparin.tw.
38 or/26-37
39 25 and 38
40 randomized controlled trial.pt.
41 controlled clinical trial.pt.
42 randomized.ab.
43 placebo.tw.
44 clinical trials as topic.sh.
45 randomly.ab.
46 trial.ti.
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47 (crossover or cross-over or cross over).tw.
48 or/40-47
49 exp animals/ not humans.sh.
50 48 not 49
51 39 and 50
Appendix 3. EMBASE search strategy
Ovid EMBASE (01.01.10 to 2 July 2012)
EMBASE is only searched one year back as the UKCC has hand searched EMBASE to this point and these trials are already in
CENTRAL.
The EMBASE search is combined with trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) http:/
/www.sign.ac.uk/mehodology/filters.html#random
There is no language restriction in this search
1 exp embryo transfer/ or exp female infertility/ or exp fertilization in vitro/
2 embryo transfer$.tw.
3 in vitro fertilisation.tw.
4 ivf-et.tw.
5 (ivf or et).tw.
6 icsi.tw.
7 intracytoplasmic sperm injection$.tw.
8 (blastocyst adj2 transfer$).tw.
9 (assist$ adj2 reproducti$).tw.
10 exp artificial insemination/
11 artificial$ inseminat$.tw.
12 reproductive technique$.tw.
13 reproduct$ technolog$.tw.
14 exp nidation/
15 (implant$ adj2 fail$).tw.
16 reproduct$ technique$.tw.
17 ((Female$ or women) adj2 infertil$).tw.
18 ((Female$ or women) adj2 subfertil$).tw.
19 exp recurrent abortion/
20 recurrent miscarriage.tw.
21 iui.tw.
22 intrauterine insemination.tw.
23 nidation.tw.
24 exp intracytoplasmic sperm injection/
25 or/1-24
26 exp HEPARIN/ or exp LOW MOLECULAR WEIGHT HEPARIN/
27 heparin$.tw.
28 LMWH$.tw.
29 liquemin.tw.
30 enoxaparin.tw.
31 heparinic acid.tw.
32 dalteparin.tw.
33 tinzaparin.tw.
34 clexane.tw.
35 lovenox.tw.
36 indenox.tw.
37 xaparin.tw.
38 or/26-37
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39 25 and 38
40 Clinical Trial/
41 Randomized Controlled Trial/
42 exp randomization/
43 Single Blind Procedure/
44 Double Blind Procedure/
45 Crossover Procedure/
46 Placebo/
47 Randomi?ed controlled trial$.tw.
48 Rct.tw.
49 random allocation.tw.
50 randomly allocated.tw.
51 allocated randomly.tw.
52 (allocated adj2 random).tw.
53 Single blind$.tw.
54 Double blind$.tw.
55 ((treble or triple) adj blind$).tw.
56 placebo$.tw.
57 prospective study/
58 or/40-57
59 case study/
60 case report.tw.
61 abstract report/ or letter/
62 or/59-61
63 58 not 62
64 39 and 63
65 (2010$ or 2011$).em.
66 64 and 65
Appendix 4. PsycINFO search strategy
Ovid PsycINFO (1806 to 2 July 2012)
There is no language restriction in this search
1 exp Reproductive Technology/
2 exp Infertility/
3 exp Embryo/
4 embryo transfer$.tw.
5 in vitro fertili?ation.tw.
6 ivf-et.tw.
7 (ivf or et).tw.
8 icsi.tw.
9 intracytoplasmic sperm injection$.tw.
10 (blastocyst adj2 transfer$).tw.
11 (assist$ adj2 reproducti$).tw.
12 artificial$ inseminat$.tw.
13 iui.tw.
14 intrauterine insemination.tw.
15 nidation.tw.
16 reproductive technique$.tw.
17 reproduct$ technolog$.tw.
18 (implant$ adj2 fail$).tw.
19 reproduct$ technique$.tw.
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20 ((Female$ or women) adj2 infertil$).tw.
21 ((Female$ or women) adj2 subfertil$).tw.
22 exp Spontaneous Abortion/
23 recurrent miscarriage$.tw.
24 or/1-23
25 exp Heparin/
26 heparin$.tw.
27 LMWH$.tw.
28 liquemin.tw.
29 enoxaparin.tw.
30 heparinic acid.tw.
31 dalteparin.tw.
32 tinzaparin.tw.
33 clexane.tw.
34 lovenox.tw.
35 indenox.tw.
36 xaparin.tw.
37 or/25-36
38 24 and 37
WH A T ’ S N E W
Last assessed as up-to-date: 6 May 2013.
Date Event Description
4 September 2014 Amended Second summary of findings table added, using random effects model. Abstract edited. No change
to overall conclusions
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